Clicky

Newron Pharmaceuticals Spa(NWPHF)

Description: Newron Pharmaceuticals S.p.A., a clinical stage biopharmaceutical company, focuses on the research and development of therapies for the treatment of central and peripheral nervous system, and pain in Italy and the United States. The company offers Xadago (safinamide) for the treatment of Parkinson's disease, as well as develops Xadago for the treatment of levodopa induced dyskinesia. It also develops Evenamide for Schizophrenia and treatment resistant schizophrenia; and Ralfinamide for orphan indication in neuropathic pain. Newron Pharmaceuticals S.p.A. was founded in 1999 and is headquartered in Bresso, Italy.


Keywords: Drugs Pain Organ Systems Parkinson's Disease Neurological Disorders Schizophrenia Treatment Of Parkinson's Disease Dyskinesia L Dopa Levodopa Levodopa Induced Dyskinesia Sodium Channel Blockers Calcium Channel Blockers Safinamide Evenamide Monoamine Oxidase Inhibitors Ralfinamide Treatment Resistant Schizophrenia Xadago

Home Page: www.newron.com

Via Antonio Meucci 3
Bresso, MI 20091
Italy
Phone: 39 02 610 3461


Officers

Name Title
Mr. Stefan Weber CEO & Exec. Director
Mr. Roberto Galli VP of Fin.
Mr. Marco Caremi Exec. VP of Bus. Devel.
Dr. Ravi Anand Chief Medical Officer

Exchange: PINK

Country: US

Currency: US Dollar ($)

Forward PE: 0
Trailing PE: 0
Price-to-Book MRQ: 3.8936
Price-to-Sales TTM: 6.3292
IPO Date:
Fiscal Year End: December
Full Time Employees: 25
Back to stocks